Rigel Pharmaceuticals (Rigel Pharmaceuticals) Days Payable : 182.27 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Rigel Pharmaceuticals Days Payable?

Rigel Pharmaceuticals's average Accounts Payable for the three months ended in Dec. 2023 was $7.6 Mil. Rigel Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $3.8 Mil. Hence, Rigel Pharmaceuticals's Days Payable for the three months ended in Dec. 2023 was 182.27.

The historical rank and industry rank for Rigel Pharmaceuticals's Days Payable or its related term are showing as below:

RIGL' s Days Payable Range Over the Past 10 Years
Min: 504.98 Med: 1863.13 Max: 5740.17
Current: 504.98

During the past 13 years, Rigel Pharmaceuticals's highest Days Payable was 5740.17. The lowest was 504.98. And the median was 1863.13.

RIGL's Days Payable is ranked better than
74.97% of 715 companies
in the Biotechnology industry
Industry Median: 148.78 vs RIGL: 504.98

Rigel Pharmaceuticals's Days Payable declined from Dec. 2022 (3,365.71) to Dec. 2023 (182.27). It may suggest that Rigel Pharmaceuticals accelerated paying its suppliers.

Rigel Pharmaceuticals Days Payable Historical Data

The historical data trend for Rigel Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Days Payable Chart

Rigel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

2,123.73

1,602.53

1,264.19

2,744.60

761.06

Rigel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															3,365.71	1,345.07	489.57	476.36	182.27

Competitive Comparison of Rigel Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Rigel Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rigel Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Days Payable falls into.

Rigel Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Rigel Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (22.508	+	7.142)	/	2 )	/	7.11	*	365
=	14.825					/	7.11	*	365
=	761.06

Rigel Pharmaceuticals's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (7.999	+	7.142)	/	2 )	/	3.79	*	365 / 4
=	7.5705					/	3.79	*	365 / 4
=	182.27

Rigel Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Rigel Pharmaceuticals (Rigel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (NAS:RIGL) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

RI2A:Germany

Address

611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080

Website

https://www.rigel.com

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Executives

Raul R Rodriguez	officer: Sr VP of Bus Dev and Com Ops	1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080
David A Santos	officer: EVP, Chief Commercial Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Wolfgang Dummer	officer: EVP & CMO	5491 OPTICAL CT., SAN JOSE CA 95138
Dean L Schorno	officer: EVP & Chief Financial Officer	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Raymond J. Furey	officer: EVP, GC & Corp Sec	1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Alison L. Hannah	director	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Brian L. Kotzin	director	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060
Kamil Ali-jackson	director	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Nelson Cabatuan	officer: Principal Accounting Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Anne-marie Duliege	officer: Chief Medical Officer	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Mayer Eldon C. Iii	officer: EVP & Chief Commercial Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Stacy Markel	officer: EVP Human Resources	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080